Nanologica AB (FRA:4YD) Cyclically Adjusted PS Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4YD Nanologica AB FRA:4YD
47 GF Score
Price €0.03
GF Value €0.30
! 9 Warning Signs
View Full Analysis

What is Nanologica AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nanologica AB  (FRA:4YD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nanologica AB Cyclically Adjusted PS Ratio Related Terms


Nanologica AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Nanologica AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Cyclically Adjusted PS Ratio Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.23 1.72

Nanologica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.58 2.41 2.44 1.72 0.84

FRA:4YD vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Nanologica AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanologica AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nanologica AB's Cyclically Adjusted PS Ratio falls into.


FRA:4YD
47GF Score
Nanologica AB FRA:4YD
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nanologica AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Nanologica AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.022/133.5600*133.5600
=0.022

Current CPI (Mar. 2026) = 133.5600.

Nanologica AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.001 101.019 0.001
201609 0.013 101.138 0.017
201612 0.031 102.022 0.041
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.004 103.279 0.005
201712 0.048 103.793 0.062
201803 0.008 103.962 0.010
201806 0.003 104.875 0.004
201809 0.006 105.679 0.008
201812 0.013 105.912 0.016
201903 0.012 105.886 0.015
201906 0.016 106.742 0.020
201909 0.011 107.214 0.014
201912 0.011 107.766 0.014
202003 0.019 106.563 0.024
202006 0.017 107.498 0.021
202009 0.007 107.635 0.009
202012 0.020 108.296 0.025
202103 0.019 108.360 0.023
202106 0.015 108.928 0.018
202109 0.007 110.338 0.008
202112 0.002 112.486 0.002
202203 0.001 114.825 0.001
202206 0.001 118.384 0.001
202209 0.001 122.296 0.001
202212 0.002 126.365 0.002
202303 0.001 127.042 0.001
202306 0.002 129.407 0.002
202309 0.001 130.224 0.001
202312 0.000 131.912 0.000
202403 0.012 132.205 0.012
202406 0.004 132.716 0.004
202409 0.001 132.304 0.001
202412 0.008 132.987 0.008
202503 0.013 132.825 0.013
202506 0.002 133.699 0.002
202509 0.003 133.480 0.003
202512 0.005 133.390 0.005
202603 0.022 133.560 0.022

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Nanologica AB (FRA:4YD) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of €0.03 is trading 89.6% below its estimated GF Value™ of €0.30.

Key valuation signals for FRA:4YD:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.30 vs. price of €0.03 (89.6% below fair value)
  • GF Score™: 47/100 with 9 warning signs

No single metric tells the full story. See the FRA:4YD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanologica AB Business Description

Other Exchanges NICA:Sweden
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
47GF Score

Get the complete analysis for FRA:4YD

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.30
GF Value